Link between Metabolic Syndrome and Insulin Resistance

Author(s): Zoran Gluvic, Bozidarka Zaric, Ivana Resanovic, Milan Obradovic, Aleksandar Mitrovic, Djordje Radak, Esma R. Isenovic

Journal Name: Current Vascular Pharmacology

Volume 15 , Issue 1 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Metabolic syndrome (MetS) is a leading public health and clinical challenge worldwide. MetS represents a group of interrelated risk factors that predict cardiovascular diseases (CVD) and diabetes mellitus (DM). Its prevalence ranges between 10 and 84%, depending on the geographic region, urban or rural environment, individual demographic characteristics of the population studied (sex, age, racial and ethnic origin), as well as the criteria used to define MetS. Persons with MetS have higher mortality rate when compared with people without MetS, primarily caused by progressive atherosclerosis, accelerated by pro-inflammatory and pro-coagulation components of MetS. Considering the high prevalence of metabolic disorders (glucose metabolism disorder, hypertension, dyslipidaemia, obesity etc.), preventive healthcare should focus on changing lifestyle in order to reduce obesity and increase physical activity. This narrative review considers the available evidence from clinical and experimental studies dealing with MetS, and current treatment options for patients with insulin resistance and MetS.

Keywords: Metabolic syndrome, insulin resistance, cardiovascular disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 13 November, 2016
Page: [30 - 39]
Pages: 10
DOI: 10.2174/1570161114666161007164510
Price: $65

Article Metrics

PDF: 109
HTML: 25